NCT01031303View on ClinicalTrials.gov

Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age

PHASE4CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

January 31, 2011

Conditions
DiphtheriaTetanusPertussisPoliomyelitis
Interventions
BIOLOGICAL

DTacP-IPV combined vaccine (TETRAXIM™)

0.5 mL, Intramuscular

Trial Locations (2)

10330

Bangkok

10400

Bangkok

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY